Bone morphogenetic protein-2 (BMP-2), a member of the transforming growth factor-β family, plays critical roles in cell differentiation, modeling and regeneration processes in several tissues. BMP-2 is also closely associated with various malignant tumors. microRNAs negatively and posttranscriptionally regulate gene expression and function as oncogenes or tumor suppressors. Herein, we report that miR-656 expression was significantly downregulated in glioma cell lines and tissues. We identified and confirmed that BMP receptor, type 1A (BMPR1A) is a direct target of miR-656. The expression of BMPR1A was negatively correlated with that of miR-656 in human glioma tissues. We further demonstrated that miR-656 suppressed glioma cell proliferation, neurosphere formation, migration and invasion with or without exogenous BMP-2. Engineered knockdown of BMPR1A diminished the antiproliferation effect of miR-656 in vitro. Moreover, the canonical BMP/Smad and non-canonical BMP/mitogenactivated protein kinase (MAPK) pathways were inhibited by miR-656 overexpression. Several cancer-related signaling molecules, including cyclin B, cyclin D1, matrix metalloproteinase-9, p21 and p27, were also involved in miR-656 function in glioma cells. The tumor-suppressing function of miR-656 was validated using an in vivo intracranial xenograft mouse model. Notably, ectopic expression of miR-656 markedly reduced tumor size and prolonged the survival of mice treated with or without BMP-2. These results elucidate the function of miR-656 in glioma progression and suggest a promising application for glioma treatment.
Introduction
Gliomas are tumors that arise from glial cells, which represent 31% of all brain and central nervous system tumors. The overall incidence rates for gliomas is 6.03 per 100 000 (1) . Gliomas are pathologically graded from low (grades I and II) to high (grades III-IV) based on the most malignant area identified (2) . Despite aggressive treatment, including surgery, adjuvant temozolomide-based chemotherapy and radiotherapy, 2-year survival with high-grade gliomas with optimal therapy is <30% (3) . Even among patients with low-grade gliomas, treatment is almost never restorative (4) . Therefore, it is urgent to investigate efficient treatment options for gliomas.
Bone morphogenetic protein-2 (BMP-2) belongs to the transforming growth factor-β superfamily and is a key regulator of cellular growth and differentiation in multiple cell types (5, 6) . BMP-2 is currently the only Food and Drug Administration (FDA)-approved osteoinductive growth factor therapy for bone regeneration and repair. Although BMP-2 has been demonstrated to promote bone fusion, clinical studies have revealed that BMP-2 elevates cancer risk (7) . Signaling of the BMP-2 cascade is comprised of two types of receptor serine/threonine protein kinases known as receptor type I and II and transcription factors belonging to the Smad family that transduce the BMP-2 signal to the nucleus (8) . Additionally, BMP-2 can rapidly induce mitogen-activated protein kinases (MAPKs) such as p38 kinase, c-Jun N-terminal kinase (JNK) and extracellular signalregulated protein kinase (ERK) 1/2, which are known to be involved in tumor cell survival in several human malignant tumors (9) . BMP-2 is upregulated in glioma tissue, especially in high grades. Levels of BMP-2 and patient survival have an inverse correlation (10); therefore, BMP-2 may be used as a marker for glioma (11) . BMP receptor, type 1A (BMPR1A) is the preferred BMP-2 type I receptor in multiple cell types (12, 13) . A large epitope for high-affinity BMPR1A binding has been observed, which spans the interface of the BMP-2 dimer (14) . BMPR1A has also been reported to be overexpressed in glioma, as indicated by microarray (15) . These observations indicate the potential function of BMP-2 in promoting glioma progression. microRNAs (miRNAs) are small non-coding single-stranded RNA molecules with ~21-25 nucleotides in length. They can trigger destruction of homologous mRNA or inhibition of cognate mRNA translation and play an important role in maintaining the stable state of chromosome structure, thereby regulating the expression of protein-coding genes (16) . Accumulating evidence indicates that miRNAs can also function as oncogenes or tumor suppressors and contribute to cancer development (17) . A recent report demonstrated that expression levels of miR-656 are significantly downregulated in human cancers, including glioma (18) , which suggests a potential inhibitory effect on glioma.
Herein, we first confirm that expression levels of miR-656 were downregulated in glioma tissues and cell lines. By suppressing BMPR1A, miR-656 inhibited glioma cell proliferation, migration, invasion and glioma cell in vivo tumor growth with or without exogenous BMP-2. Our results suggest that miR-656 may represent a therapeutic target for glioma treatment.
Materials and methods

Tissue specimens
Surgically excised tumor specimens from 50 patients with World Health Organization (WHO) grades II-IV glioma (14 patients with grade II, 20 with grade III and 16 with grade IV gliomas) and 5 normal brain tissues were obtained from the Department of Neurosurgery, Hospital of Harbin Medical University, China. Collected tissues were immediately snap frozen and stored at −80°C. This research was approved by the Institutional Review Board of Harbin Medical University, and all participants have given written informed consent.
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manufacturer's instructions. Complementary DNA was synthesized from 5 ng of total RNA, using the Taqman miRNA reverse transcription kit (Applied Biosystems). The expression levels of miR-656 were quantified using the miRNA-specific TaqMan miRNA assay kit (Applied Biosystems). Expression levels of miRNA were calculated using the 2 −ΔΔCt method, with U6 snRNA as endogenous control. Detection of mRNA was performed as described previously (19) . The sequences of the primers were as follows: BMPR1A forward, 5′-TAGTTCGCTGAACCAATAAAGG-3′; BMPR1A reverse, 5′-GTCAGAAAATGGAGTAACCTTA-3′; GAPDH forward, 5′-TG GACTCCACGACGTACTCAG-3′; GAPDH reverse, 5′-CGGGAAGCTTGTC ATCAATGGAA-3′.
Western blots U87 and U373 cells were transfected with 50 nM miR-656, miR-656 mutant (miR-656-mut), miR-656 inhibitor (miR-656-in) or negative control (NC) for 2 days. Cells were starved overnight in DMEM + 0.1% FBS medium before treatment with BMP-2 (100 ng/ml). Cells were lysed in radioimmunoprecipitation assay buffer [150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 50 mM Tris, pH 8.0, 5.0 mM ethylenediaminetetraacetic acid, pH 8.0, 0.5 mM dithiothreitol and 1 mM phenylmethylsulfonyl fluoride]. Protein concentrations were determined using the bicinchoninic acid method (Thermo Scientific, Rockford, IL). Protein lysates were separated by SDS-polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membranes (Millipore, Billerica, MA) by electroblotting. Primary antibodies for immunodetection were anti-BMPR1A
, anti-p21 (Abcam) and anti-GAPDH (Santa Cruz). Subsequent to being incubated with anti-rabbit or anti-mouse secondary antibodies (Santa Cruz) for 1 h, the immune complexes were detected using the enhanced chemiluminescence method.
Plasmids, siRNA, transfections and luciferase assay miR-656, miR-656-mut, miR-656-in, NC, scramble siRNA and siRNA targeting BMPR1A were purchased from GenePharma (Shanghai, China). The wild-type full-length BMPR1A 3′ untranslated region (UTR) was amplified from the genomic DNA and then ligated into the hRluc/TK luciferase reporter vector (Promega, Madison, WI). Transformants were grown up, and plasmid DNAs were confirmed by sequencing and then were transfected with miR-656 or NC (10 or 50 nM, respectively) sequences into U87 or U373 cells, using X-tremeGENE (Roche, Mannheim, Germany). Id1 luciferase reporter plasmid was purchased from Addgene (Cambridge, MA). Renilla luciferase plasmid (Promega) was cotransfected to normalize the relative luciferase values. At 48 h posttransfection, cell lysates were collected to determine luciferase activity with the dual-luciferase reporter assay system (Promega). The transfection of siRNAs was performed using X-tremeGENE per the manufacturer's instruction. The BMPR1A gene was PCR amplified from U87 cDNA as a BamHI-NotII fragment and cloned into a pcDNA3.1 vector (Invitrogen). The forward primer sequence for cloning was CGCGGATCCATGCCTCAGCTATAC ATTTAC ATCAGATTA, and the reverse primer sequence was ATAGTTTAGCGGCCGCT CAGATTTTTACATCTTGGGATTCAACCATCTT. Transfection of BMPR 1A-pcDNA3.1 plasmid was performed using X-tremeGENE.
MTS assay
Cells were plated at a density of 2000 cells per well in 96-well plates and transfected with 50 nM miR-656 or NC for 2 days. After overnight starvation in DMEM + 0.1% FBS medium, BMP-2 (100 ng/ml) was added to the medium. Twenty microliters of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS; Promega) was added into each well containing 100 µl medium after cells were cultured for 0, 1, 2 and 3 days. The cells were then incubated at 37°C for 2 h in a humidified 5% CO 2 incubator. Absorbance was detected at 490 nm with a microplate reader (Bio-Rad).
5-Ethynyl-2′-deoxyuridine assay
5-Ethynyl-2′-deoxyuridine (EdU) assays were performed using the EdU kit (Invitrogen) according to the manufacturer's instructions. Cells (1 × 10 5 ) per well were seeded in triplicate in four-well chamber slides for 24 h and transfected with 50 nM miR-656 or NC for 2 days, followed by 100 ng/ml BMP-2 treatment for 24 h. Next, cells were exposed to 20 µM EdU for an additional 4 h at 37°C. The cells were fixed, permeabilized and then incubated with Click-iT® reaction cocktail for 1 h, followed by Hoechst 33342 (5 µg/ml) nuclear staining for 30 min. The cells were counted under six random microscopic fields for each well, using NIH Image J software.
Gelatin zymography U87 and U373 cells were first transfected with 50 nM miR-656 or NC for 2 days and then starved in DMEM + 0.1% FBS medium overnight. Then cells were treated with 100 ng/ml BMP-2, collected at different time points, and subsequently incubated in SDS-loading buffer without a reducing agent at room temperature for 10 min. Cell lysate samples were loaded onto SDSpolyacrylamide gels that were polymerized with 0.1% gelatin as substrate. After electrophoresis, the gels were re-natured in 2.5% Triton X-100 and incubated in developing buffer (50 mM Tris-HCl, pH 7.4) in the presence of 5 mM CaCl 2 overnight at 37°C. The gels were then stained with 0.5% Coomassie blue R-250 and destained in 10% methanol and 5% acetic acid in water. Gelatinase activity was visualized as transparent bands on a blue background.
Cell cycle
Cells (2 × 10 6 /ml) were transfected with 50 nM miR-656 or NC for 2 days and starved overnight in DMEM + 0.1% FBS medium. Cells were then treated with 100 ng/ml BMP-2 for 24 h. After treatment, cells were collected, washed with phosphate-buffered saline twice and fixed with ice-cold 70% ethanol. After fixation, cells were incubated with RNase I (1 µg/ml) at 37°C for 1 h. Samples were analyzed by flow cytometry (LSRII; BD Biosciences, San Jose, CA) after propidium iodide (20 µg/ml) was added.
Neurosphere formation assay Cells (5 × 10 3 ) per well were seeded into 24-well plates in triplicate. miR-656 (50 nM) or NC was transfected into U87 and U373 cells for 2 days. Then cells were cultured in neural stem cell medium (Invitrogen) with 20 ng/ml epidermal growth factor, 20 ng/ml fibroblast growth factor and 2 µg/ml heparin supplement (Invitrogen) in the absence or presence of BMP-2 (100 ng/ml). Media was changed every 2 days. The numbers of neurospheres with a diameter >50 µm were counted using NIH Image J software at 10 days.
Wound-healing assay
Cells were grown to 80% confluence in 24-well plates and then transfected with 50 nM miR-656 or NC for 2 days. Cells were starved overnight in DMEM + 0.1% FBS medium. The cellular layer was wounded using a sterilized tip. Cell migration was monitored after 24 h with or without BMP-2 treatment (100 ng/ml) and microscopically photographed. Migration ability was assessed by measuring changes in sizes of wounded areas.
Invasion assay
The ability of cells to invade through a Matrigel-coated filter was measured in transwell chambers (pore size 8 µm; BD Biosciences). The membranes of filters were coated with basement membrane Matrigel (50 µl per filter) (BD Biosciences). Cells were transfected with 50 nM miR-656 or NC for 2 days and starved overnight in DMEM + 0.1% FBS medium. Cells (1 × 10 5 ) were then trypsinized and added to the upper chamber. The lower chamber was filled with 0.6 ml of DMEM + 0.1% FBS medium with or without 100 ng/ml BMP-2. After incubation for 24 h, the cells on the upper surface of the membrane were removed by a cotton swab. The migrating cells on the lower membrane were stained with calcein acetoxymethyl ester (4 µg/ml; BD Biosciences) in phosphate-buffered saline for 30 min and were observed by fluorescence microscopy (Olympus). We imaged six fields per filter and counted the average numbers of cells per field as a measure for cell invasion.
Intracranial glioma xenografts
All animal procedures were conducted in accordance with the Guide for the Care and Use of Laboratory Animals of Harbin Medical University and approved by the Chancellor's Animal Research Committee. Male immunedeficient BALB/c nude mice (7-8 weeks old) were purchased from Beijing Wei-tong Li-hua Laboratory Animals and Technology Ltd and were randomly divided into four groups: U87/lentivirus-NC (System Biosciences); U87/lentivirus-NC + BMP-2; U87/lentivirus-miR-656 and U87/lentivirus-miR-656 + BMP-2 (n = 14 mice in each group). U87 cells were infected with 20 multiplicity of infection of miR-656-expressing lentivirus or control lentivirus by spin infection for 2 h, followed by incubation at 37°C for 2 h. To determine the transduction efficacy of U87 cells with lentivirus-miR-656, cells were cultured in DMEM + 10% FBS for 3 days, and miR-656 and BMPR1A expression was subsequently performed by real-time polymerase chain reaction (RT-PCR) analysis and western blot, respectively. The intracranial xenograft mouse model of human glioma was conducted as described previously (20) . Cells (5 × 10 5 ) infected with lentivirus-NC or lentivirus-miR-656 were engrafted into the right cerebral hemisphere of each mouse. BMP-2 (100 µg/kg) was intravenously injected into mice daily. Four mice from each group were euthanized, and tumors harvested for histologic analysis 12 days postimplantation. Tumor size was determined by microscopically measuring tumor areas of median sections as a representative. Each section was analyzed by Image-Pro Plus (Media Cybernetics). For survival studies, animals were kept until they M.Guo et al.
reached physiologic criteria for early removal or euthanasia. Kaplan-Meyer survival curve analysis was performed for each group.
Immunohistochemistry
Mouse brains were fixed in 4% paraformaldehyde at 4°C for 48 h and then embedded in paraffin. The sections (5 µm) were deparaffinized and treated with 3% hydrogen peroxide for 10 min to block endogenous peroxidase activity. Slides were incubated with rabbit polyclonal anti-BMPR1A (1:100) overnight at 4°C after blocking with 1% bovine serum albumin. The next day, sections were incubated with biotinylated goat anti-rabbit secondary antibody (Santa Cruz) for 1 h at room temperature. VECTSTAIN Elite ABC complex (Vector Lab, Burlingame, CA) incubation was followed by development with AEC chromogen (Dako, Carpinteria, CA). NC sections were incubated in phosphate-buffered saline instead of primary antibody.
Statistical analysis
The data are shown as mean ± standard error of the mean. Differences among groups were analyzed by one-way analysis of variance, followed by Bonferroni post hoc analyses, as appropriate. P value ≤0.05 was taken to indicate significant differences. All statistical analyses were conducted using SPSS 17.0.
Results
miR-656 is downregulated in human glioma cell lines and tissues
The published microarray (NCBI/GEO/GSE25631; n = 87, P ≤ 0.01, five normal brain samples, 82 primary glioma samples of WHO grade IV) showed that miR-656 was highly regulated, and its expression was lower in primary glioblastoma multiform than in normal brain tissue ( Figure 1A ). To explore whether downregulation of miR-656 in glioma cell lines is clinically relevant, we further determined miR-656 levels in primary glioma tissue of various grades of malignancy (five WHO grade II, five WHO grade III and five WHO grade IV) and compared them with two normal brain tissue samples. The results showed that miR-656 levels were significantly lower than in normal brain tissue ( Figure 1B) . Additionally, RT-PCR analysis showed that the expression of miR-656 was markedly downregulated in six human glioma cell lines, including U87vlll, U87, T98G, LN229, U373 and U251, as compared with the NHA cell line ( Figure 1C) . Collectively, this suggests that miR-656 is downregulated in both glioma cell lines and tissues.
miR-656 directly targets BMPR1A
We used publicly available algorithms (TargetScan, miRanda, miRNA) and found that BMPR1A is one of the potential targets of miR-656. There are four putative miR-656 target sites located in different sections of the BMPR1A 3′UTR (Figure 2A) . To obtain direct evidence that miR-656 targets BMPR1A, we designed a miR-656 mutant (miR-656-mut) that mutated five common nucleotides in four miR-656 BMPR1A target sites ( Figure 2B ). We first examined the efficiency of miR-656 transfection, by measuring miR-656 expression. miR-656 levels increased 17-fold in U87 and 16-fold in U373 cells 2 days posttransfection when compared with day 0 and then decreased to normal levels on the eighth day posttransfection ( Figure 2C and Supplementary Figure 1A , available at Carcinogenesis Online). Western blot analysis showed that BMPR1A expression was dramatically decreased in U87 and U373 cells transfected with miR-656 compared with cells transfected with NC or miR-656-mut ( Figure 2D and Supplementary Figure 1B , available at Carcinogenesis Online). To further confirm that BMPR1A is a target of miR-656, a luciferase reporter carrying the BMPR1A 3′UTR was cotransfected with NC, miR-656 or miR-656-mut into glioma cells. As shown in Figure 2E and Supplementary Figure 1C , available at Carcinogenesis Online, miR-656 significantly reduced luciferase activity linked with the 3′UTR of BMPR1A in a dose-dependent manner in both U87 and U373 cells, whereas miR-656-mut did not show any suppressive effects. To further investigate whether miR-656 inhibition affects BMPR1A expression, we transfected miR-656-in to U87 and U373 cells. Western blot results showed that BMPR1A expression was elevated by miR-656-in when compared with NC ( Figure 2F and Supplementary Figure 1D , available at Carcinogenesis Online). Accordingly, luciferase activity driven by transcription of 3′UTR-BMPR1A was stimulated by miR-656-in ( Figure 2G and Supplementary Figure 1E , available at Carcinogenesis Online). We next investigated BMP-2 and BMPR1A expression levels in human glioma specimens from published microarray data (NCBI/ GEO/GDS1813/41230/BMP-2 and NCBI/GEO/GDS1813/2396/ BMPR1A; n = 53, P ≤ 0.01; four normal brain samples, 53 primary glioma samples of different types). Notably, the levels of both BMP-2 and BMPR1A were significantly lower in normal brain tissue compared with those in gliomas ( Figure 2H and Supplementary Figure 2A , available at Carcinogenesis Online). To determine whether expression of BMPR1A is associated with miR-656 in patients with glioma, miR-656 and BMPR1A levels were examined in different grades of glioma specimens from 50 patients. Spearman's correlation analysis showed that expression of miR-656 was inversely correlated with that of BMPR1A ( Figure 2I , r = −0.72; P < 0.01). Taken together, these results established BMPR1A as a bona fide target of miR-656.
Overexpression of miR-656 inhibits glioma cell proliferation stimulated by BMP-2
To study the effects of miR-656 regulation of BMPR1A on glioma tumorigenesis, we first tested the effects of miR-656 on glioma cell growth with or without BMP-2 treatment. MTS assays were performed to determine the effects of different doses of BMP-2 (0, 25, 50, 100, 250, 500 ng/ml) on glioma cell proliferation, using six glioma cell lines (U87vlll, U87, T98G, LN229, U373 and U251). We observed that BMP-2 markedly increased glioma cell proliferation in a dose-dependent manner when the concentration was <100 or 250 ng/ ml ( Figure 3A and Supplementary Figures 3A-D and 4A , available at Carcinogenesis Online). Therefore, we chose the dose of 100 ng/ml BMP-2 for further experiments. Interestingly, overexpression of miR-656 significantly reduced cell proliferation and inhibited the ability of BMP-2 to promote glioma cell growth on days 2 and 3 ( Figure 3B and Supplementary Figure 4B , available at Carcinogenesis Online). To confirm these results, we assessed cell cycle by flow cytometry. As shown in Figure 3C and Supplementary Figure 4C , available at Carcinogenesis Online, treatment with BMP-2 for 24 h decreased proportion of cells in G 1 phase from 60% to 40%, which can be restored by miR-656 overexpression. Moreover, miR-656 itself increased 20% of G 1 phase cells compared with NC. The EdU assay consistently revealed a 2-fold increase in proliferating cells by BMP-2 treatment.
By contrast, such a change was not observed in the expression of miR-656. In addition, without BMP-2 treatment, miR-656 overexpression reduced the average number of cells stained with EdU by 2-fold compared with NC ( Figure 3D and Supplementary Figure 4D , available at Carcinogenesis Online). To confirm the repressive role of miR-656 in glioma progression via targeting of BMPR1A, we knocked down BMPR1A, using BMPR1A siRNA. Our data showed that downregulation of BMPR1A significantly inhibited glioma cell proliferation, whereas miR-656 did not further reduce cell proliferation (Figure 3E and Supplementary Figure 4E , available at Carcinogenesis Online). Collectively, these results suggest that BMPR1A is required for the suppressive role of miR-656 for glioma cell proliferation with or without exogenous BMP-2.
Upregulation of miR-656 suppresses glioma cell neurosphere formation, migration and invasion activated by BMP-2
Next, to address the role of miR-656 in regulating glioma cell neurosphere formation, U87 and U373 cells were cultured in neural stem cell medium with or without BMP-2 (100 ng/ml) after NC or miR-656 transfection. As shown in Figure 4A and Supplementary Figure 5A , available at Carcinogenesis Online, fewer miR-656-transduced U87 and U373 cells grew into 3D spheres compared with the NC cells. BMP-2 treatment dramatically increased the numbers of neurospheres per microscopic field by ~2-fold; however, there was no detectable effect of BMP-2 on miR-656-overexpressing cells. In addition, we conducted a wound-healing assay to examine glioma cell migration. miR-656 by itself significantly weakened the migration capabilities of glioma cells compared with NC. As expected, BMP-2-treated cells migrated significantly faster than control cells, and this accelerated effect on migration was partially abrogated by miR-656 ( Figure 4B and Supplementary Figure 5B , available at Carcinogenesis Online). Finally, transwell assays were performed in glioma cells to assess their strong ability to invade. As shown in Figure 4C and Supplementary Figure 5C , available at Carcinogenesis Online, when cells were treated with BMP-2, the numbers of cells migrating through the transwell insert increased 2-fold. On the other hand, miR-656 suppressed cell invasion when treated with or without BMP-2. In summary, upregulation of miR-656 suppresses glioma cell neurosphere formation, migration and invasion with or without BMP-2 treatment. 
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miR-656 regulates BMP-2 signaling in glioma cells
We next investigated how miR-656 regulates the BMP-2 signaling pathway in glioma cells. We first treated U87 cells with BMP-2 (100 ng/ml) for different time periods (0, 5, 15, 30 and 120 min) and then examined the activation of Smads and MAPKs. Western blotting results revealed that BMP-2 quickly promoted the phosphorylation of Smad1/5/8, P38, JNK and ERK1/2 ( Figure 5A ) starting at 5 min and peaking at 30 min. We then examined Smad and MAPK activity in four groups of U87 cells (NC, NC + BMP-2, miR-656 + BMP-2 and miR-656) 30 min after BMP-2 treatment. The results showed that miR-656 markedly inhibited Smad1/5/8, p38, JNK and ERK1/2 phosphorylation with or without BMP-2 stimulation ( Figure 5B ). BMP-2 activates Smad1/5/8, which could in turn bind to Id1 gene promoter and stimulate Id1 transcription (21) . Luciferase reporters that carry Id1 promoter were used here to examine the activation of BMP-2/ Smad signaling pathway. Our results showed that miR-656 inhibited Id1 promoter luciferase assays in cells treated with or without exogenous BMP-2 ( Figure 5C ), which further supports the direct regulation of BMP-2 signaling by miR-656. Our previous data indicated that miR-656 affects glioma cell proliferation, so we evaluated the regulation by BMP-2 and miR-656 of several genes related to cancer cell growth, including cyclin A, cyclin B, cyclin D1, cyclin E, p21 and p27. We found that expression of cyclin B and cyclin D1 was increased, whereas levels of p21 and p27 were decreased by BMP-2 (100 ng/ml) ( Figure 5D ). We did not observe any change in cyclin A and cyclin E expression (data not shown). As expected, BMP-2 activation of cyclin B, cyclin D1, p21 and p27 was significantly inhibited by miR-656 ( Figure 5E ).
Increased expression of the cancer-related signaling molecule matrix metalloproteinase-9 (MMP-9) has been correlated with cancer invasion (22) . We conducted gelatin zymography assays to analyze MMP-9 activity in U87 cells posttreated with BMP-2 (100 ng/ ml) at various time points. We found that BMP-2 activates MMP-9 ( Figure 5F ), and this effect can be abolished by miR-656 ( Figure 5G ). Taken together, our results indicate that BMP-2 stimulates the Smad and MAPK pathways, increases cyclin B, cyclin D1 and MMP-9 expression and decreases p21 and p27 expression in glioma cells, which can be inhibited by miR-656.
miR-656 upregulation inhibits U87 cell tumor growth in vivo
Our in vitro results strongly suggest that miR-656 directly targets BMPR1A and suppresses glioma cell proliferation, neurosphere formation, migration and invasion. To further analyze the biological role of miR-656 in vivo, we implanted engineered U87 cells stereotactically into nude mice brains. First, the transduction efficacy of lentivirus-miR-656 in U87 cells was determined in vitro by evaluating miR-656 levels. As shown in Figure 6A , miR-656 levels increased 10-fold 3 days after transduction compared with NC. Subsequently, we observed a downregulation of BMPR1A in lentivirus-miR-656 transduced cells ( Figure 6B ). Furthermore, we verified the downregulation of BMPR1A in vivo, using xenografted tumor samples treated with miR-656 ( Figure 6C ). Interestingly, histopathologic staining revealed significant increases of tumor sizes in mice treated with BMP-2 compared with control ( Figure 6C ). However, tumor sizes were smallest in the miR-656 group. There was no obvious difference between the control group and the miR-656 with BMP-2-treated group ( Figure 6D) . Accordingly, the median survival time in NC group is 27 days. The miR-656 + BMP-2 group's survival time is 23.5 days close to NC group. BMP-2 treatment shortened the median survival time of NC group to 17 days. In contrast, miR-656 improved survival time to 36 days compared with the other groups ( Figure 6E ). Taken together, these results confirm that overexpression of miR-656 inhibits glioma cell tumor formation in vivo in the absence or presence of exogenous BMP-2, thereby alleviating cancer progression.
Discussion
Glioma is one of the most commonly occurring tumors in the central nervous system (1) . An improved understanding of glioma biology and therapy options is needed. Herein, we determined that miR-656 represents a miRNA species strikingly downregulated in glioma cell lines and tissues. miR-656 evidently decreases BMPR1A expression by directly targeting BMPR1A 3′UTR. Examination of clinical glioma samples showed that miR-656 levels are negatively correlated with BMPR1A expression. Moreover, we demonstrated, for the first time, that BMP-2 treatment causes marked stimulation of glioma cell growth, migration and invasion. miR-656 regulates the BMP-2 signaling pathway and confers in vitro and in vivo inhibition of glioma tumorigenesis with or without exogenous BMP-2. Thus, our study provides new insights into the role of miR-656 in glioma and its function in regulating BMP-2 signaling.
Malignant tumor progression is a highly orchestrated process that requires complex transcription and posttranscriptional regulation of gene expression (23) . Recent findings demonstrate that miRNAs tend to work at the periphery of developmental networks to play an important role in this regulation (24) . These small non-coding RNAs perform their function via base-pairing with complementary sequences within mRNA molecules, usually resulting in gene silencing via translational repression or target degradation (25) . A large number of miRNA have been found to promote or repress brain tumor development. miR-656 belongs to the miR-379/miR-656 miRNA cluster, one of the largest known miRNA clusters in vertebrates (26) . Many mature miRNAs derived from this cluster have been experimentally identified and investigated (27, 28) . However, only studies of miR-656 expression in cancer cells have been reported (18, 29) . There is a lack of functional research on this particular miRNA. Herein, we established that miR-656 is an effective glioma suppressor. BMP-2, like other BMPs, plays an important role in development of the skeletal system (30) . Due to its efficient effects on bone regeneration, the United States FDA has approved Recombinant Human BMP-2 (rhBMP-2) ('Amplify', Medtronic) for clinical use. However, the FDA reported that rhBMP-2 increased cancer rates with nine (3.8%) new tumors among 239 patients versus only two (0.9%) among 224 control patients. Subsequently, at 60 months, cancer rates increased to 5% in the BMP-2 group versus 2.1% among control patients (31) . Patients with an active malignancy or undergoing treatment for malignancy are limited to use rhBMP-2. The effect of BMP-2 on cancer development and progression has been a focus of investigation. In several reports, a promoting effect of BMP-2 has been found for human cancer cells and human cancer cell lines, such as gastric cancer (32) , malignant peripheral nerve sheath tumors (33) , pancreatic cancer (34), breast cancer (35) , oral carcinoma (36), lung cancer (37) and prostate cancer (38) . Although it was reported that BMP-2 is overexpressed in glioma samples and patients serum (10, 11) , the effects of BMP-2 on glioma tumorigenesis are unknown. In this study, we evidenced for the first time that BMP-2 dramatically promotes glioma cell proliferation, neurosphere formation, migration and invasion, and our in vivo data further confirmed that BMP-2 significantly increased glioma tumor sizes. We note that BMP-7, another BMP family member, was found to inhibit the glioma cells (39) , which may be due to BMP-2 and BMP-7 having different receptor preferences (13) .
BMPRs are a group of transmembrane serine/threonine kinase receptors. BMPs transduce their signals through interacting with BMPRs. There are four different type I receptors-BMPR1A, activin receptorlike kinase (ALK) 1, ALK2 and BMPR1B-and three distinct type II receptors (40) . The binding of BMP-2 to BMPRs induces formation of heteromeric receptor complexes in which the type II receptor phosphorylates and thereby activates the type I receptor. Type I BMPR is the initial high-affinity anchoring receptor for BMP-2 (41). In the case of BMPR1A, BMP-2 directly binds the BMPR1A ectodomain by hydrophobic interaction (42) . Overexpression of BMPR1B can reduce the malignancy of glioblastoma cells (43) , but the effects of up-or downregulation of BMPR1A on glioblastoma are unknown. Interestingly, upregulation of BMPR1A did not affect glioma cell proliferation, neurosphere formation, migration or invasion, which, we suspect, is due to the already high endogenous levels of BMPR1A (Supplementary Figure 6A -F, available at Carcinogenesis Online). Our findings suggest that downregulation of BMPR1A may contribute to glioma suppression.
Smad proteins play an important role in transduction of external BMP-2 signaling toward the cell nucleus, where the expression of specific target genes is controlled (44) . However, BMP-2 can also initiate intracellular signaling through stimulation of downstream substrates, including P38, JNK and ERK1/2 of three MAPK cascades (34, 45) . Both BMP-2-stimulated Smad and MAPK pathways were mediated by BMP receptor heteromeric complexes (46) , which is consistent with our finding that downregulation of BMPR1A by miR-656 alleviates phosphorylation of Smad, P38, JNK and ERK1/2 activated by BMP-2. We also observed that certain oncogenic or tumor suppressor proteins, including cyclin B, cyclin D1, p21 and p27 and MMP-9, are involved in the functions of BMP-2 in glioma. More importantly, these molecules can also be regulated by miR-656.
This study reveals the key role of miR-656 in regulating glioma carcinogenesis through its functionally relevant mRNA target, BMPR1A, which may prove to be a useful candidate for new therapeutic applications for glioma. Even though the functions of some miRNA in the pathogenesis and treatment of glioma have been elucidated, there are still many other miRNA that potentially play pivotal roles, making their discovery and investigation imperative. Supplementary Figures 1-6 can be found at http://carcin.oxfordjournals.org/
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